Waystar Holding (WAY) is back in the spotlight after expanding its collaboration with Google Cloud to further integrate its Gemini model and advanced data infrastructure into its AI-driven revenue cycle platform.
Check out our latest analysis for Waystar Holding.
Despite the AI headlines and growing Google Cloud partnership, Waystar’s 30-day price return of 5.8% is in line with its 90-day stock price decline of 22.6% and one-year total shareholder return loss of 31.3%. This suggests that sentiment has been weak recently, despite increased interest in the company’s Healthcare AI story.
If this Google Cloud news has you thinking about other areas where AI is reshaping healthcare, now might be a good time to take a look at our list of 32 healthcare AI stocks.
While the stock has fallen over the past year, with an intrinsic value gap of around 43% and trading at a similar discount to the average analyst target, you have to ask yourself, is this an opportunity for a reset, or is the market already pricing in future growth?
Most Popular Stories: 30.5% are underrated
The most popular theory of $25.71 pegs Waystar’s fair value at $37.00, and today’s price would be a significant difference from that estimate.
The acquisition of Iodine Software, a leading provider of AI-powered clinical intelligence, expands Waystar’s total addressable market by more than 15%, accelerates its product roadmap, immediately improves gross margins and adjusted EBITDA margins, and establishes compounding long-term revenue and revenue growth. Facing increased administrative complexity, demands for interoperability, and changing payer dynamics, providers are prioritizing the adoption of robust cloud-based RCM software like Waystar. Waystar has demonstrated superior automation and ROI for customers, supporting both strong new customer acquisition and high net revenue retention, likely driving sustained double-digit sales growth.
Read the whole story.
Curious about what’s behind the fair value and AI augmentation story? This story hinges on higher future margins, faster revenue growth, and richer earnings multiples than today suggests.
This story uses a discount rate of 8.94% and combines expected revenue growth, margin expansion, and future P/E ratio assumptions to arrive at a fair value of $37.00. Analysts following this trend expect earnings and revenue to grow faster than the overall U.S. market over the next few years, increasing profitability from today’s starting point. The result is a picture in which a company that just turned profitable is modeled to meaningfully grow its earnings from here on out.
Result: Fair value $37.00 (undervalued)
Read the full explanation to understand what’s behind the predictions.
However, the story hinges on whether future margin improvements and AI adoption land as expected, although acquisition leverage and fast-moving competitors could challenge these assumptions.
Learn about the key risks to this Waystar Holding story.
Another angle: Multiple paints a grimmer picture
There’s a bit of a twist when looking at Waystar’s price-to-earnings ratio. The company’s P/E ratio is approximately 44x, which is significantly higher than the estimated fair multiple of 27.4x, the global healthcare service average of 30.6x, and the average of peers of 29x. This shows the valuation risk if expectations cool.
See what the numbers say about this price in our valuation breakdown, and decide whether the discounted cash flow view or the richer earnings multiple makes more sense. See what the numbers say about this price. Please check the rating breakdown.
next step
If you’re unsure about the mix of AI optimism and valuation questions, quickly take a look at the big picture and form your own view. Our research highlights multiple potential upside factors that the market is watching. So it’s worth researching the details of these four key benefits for yourself.
Looking for more investment ideas?
The hard part is already done for you by finding out more about Waystar, so don’t stop here when others on the market may be offering something better suited to your goals.
This article by Simply Wall St is general in nature. We provide commentary using only unbiased methodologies, based on historical data and analyst forecasts, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.
Evaluation is complex, but we will simplify it here.
Discover whether Waystar Holdings is undervalued or overvalued with our in-depth analysis. Fair value estimates, potential risks, dividends, insider transactions, and financial condition.
Access free analysis
Do you have feedback on this article? Interested in its content? Please contact us directly. Alternatively, email editorial-team@simplywallst.com.
